Main menu

- News
- Publications
Donate

Search
Contact Us
Member Login

A pilot study of chemoimmunotherapy in the postconsolidation setting for high-risk neuroblastoma (ANBL19P1): A report from the Children’s Oncology Group. Cancer

January 15, 2026

Footer

Footer links

Impact
Patients & Families
Collaborate
Ways to Give
News
Request for Proposals
Careers
Privacy Policy
Terms of Use

Social media

The information and content provided on this website is made available for informational purposes only for children and their families affected by cancer. While the Children’s Oncology Group strives to provide accurate and up-to-date information, the information may be out of date or incomplete in certain respects. Please do not rely on this information and seek the care of a qualified medical professional if you have questions regarding a specific medical condition, disease, diagnosis or symptom. The information and content presented herein is not intended to replace the independent clinical judgement, medical advice, screening, health counseling, or other intervention performed by your (or your child’s) health care provider. Please contact “911” or your emergency services if this is a health emergency. No endorsement of any specific tests, products, or procedures is made herein.